Author:
Anderson Claire L.,Darbari Deepika S.
Publisher
Springer International Publishing
Reference136 articles.
1. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–48.
2. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012;59(2):365–71.
3. Sciences USDoHaH. Evidence-based management of sickle cell disease. Bethesda, MD: National Institute of Health, National Heart, Lung, and Blood Institute; 2014. http://www.nhlbi.nih.gov/guidelines. Accessed 11 Jan 2014
4. Serjeant GR. Fetal haemoglobin in homozygous sickle cell disease. Clin Haematol. 1975;4(1):109–22.
5. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652–6.